Elmiron pentosan polysulfate maculopathy vision loss lawsuit MDL 2973 guide

Elmiron Maculopathy Vision Loss Lawsuit MDL 2973: Eligibility and Claims Guide 2026

Daylongs · May 21, 2026 · 8 min read

#MDL 2973 #Elmiron lawsuit #pentosan polysulfate #maculopathy #vision loss #Janssen #mass tort

Disclaimer: This post is for general information only and not legal advice. Consult a licensed US attorney for your specific situation.

What Is Elmiron and Who Uses It?

Elmiron (generic name: pentosan polysulfate sodium, or PPS) holds a unique and critical position in American medicine: it is the only FDA-approved oral drug for treating interstitial cystitis (IC), a debilitating chronic bladder condition causing pelvic pain, urinary urgency, and frequency. Up to 12 million Americans are estimated to suffer from IC, with women disproportionately affected.

Since receiving FDA approval in 1996, Elmiron has been prescribed to hundreds of thousands of IC patients. Because interstitial cystitis is a chronic condition with no cure, many patients take Elmiron for years or decades continuously. It is this long-term use that creates the foundation for the litigation.

The drug is manufactured and sold by Janssen Pharmaceuticals, a wholly-owned pharmaceutical subsidiary of Johnson & Johnson.

The Science: How Elmiron Damages the Retina

The discovery of Elmiron’s ocular toxicity began with careful clinical observation. Ophthalmologists treating IC patients started noticing a distinctive and previously undescribed pattern of retinal damage that did not fit the known profiles of age-related macular degeneration (AMD), diabetic maculopathy, or other recognized conditions.

Pigmentary Maculopathy Explained

The macula is the central area of the retina responsible for sharp, detailed central vision — the vision used for reading, recognizing faces, and detailed work. In Elmiron-associated maculopathy:

The retinal pigment epithelium (RPE) cells — which support and nourish the photoreceptors — accumulate damage over time
The pattern of damage is distinctive and recognizable under retinal imaging
Damage appears to accumulate with longer duration and higher cumulative dose of Elmiron

Key Research Findings

A landmark 2019 ophthalmology study found:

Finding	Data
Prevalence in 5+ year users	Approximately 25% developed significant retinal changes
Risk factor	Duration of use and cumulative dose
Reversibility	Potentially permanent in many cases
Unique pattern	Not seen in other drug-induced maculopathies

Symptoms: When to See a Retinal Specialist

If you have taken Elmiron for an extended period — especially more than one year — watch for:

Symptom	Description
Reading difficulty	Text appears blurry or distorted
Dark adaptation problems	Slow recovery of vision when entering dim lighting
Blurred vision	General lack of visual sharpness
Blind spots	Missing areas within your field of vision
Metamorphopsia	Straight lines appear wavy or curved
Color vision changes	Difficulty distinguishing colors

Do not wait: Schedule an eye examination with a retinal specialist or ophthalmologist, specifically requesting evaluation for pentosan polysulfate maculopathy. Bring your complete medication history. Early detection may allow treatment adjustments that slow progression.

FDA Actions: The Black Box Warning

June 2020: Black Box Warning Added

In June 2020, after review of accumulating research evidence, the FDA approved significant label changes for Elmiron, adding a black box warning — the strongest safety alert the FDA can require on a prescription drug label.

The warning specifically states:

Elmiron can cause retinal pigmentary changes, including maculopathy, with long-term use… Patients should be instructed to report any visual disturbances to their prescribers.

Why the Timing Matters Legally

Plaintiffs argue that Janssen possessed or should have possessed earlier evidence of macular toxicity — potentially predating the 2020 warning by years. The failure to warn theory holds that Janssen had a duty to update prescribing information and patient labeling earlier, and that its delay caused patients who might have stopped taking Elmiron sooner to suffer greater retinal damage.

MDL 2973: The Federal Litigation

Case Overview

Full case name: In re: Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation, MDL No. 2973
Court: U.S. District Court, District of New Jersey
Judge: Brian R. Martinotti
Established: December 2020
Initial case count: Approximately 2,000 cases
As of October 2025: Approximately 730 cases pending

Interpretation of Declining Case Count

The decline from ~2,000 to ~730 cases between December 2020 and October 2025 indicates that confidential settlements have been reached for a significant portion of cases. This is standard in mass tort MDLs — individual settlements are reached without public disclosure of amounts.

Bellwether Trials

In MDL proceedings, bellwether trials are selected test cases representing different claim types and injury profiles. Results from these trials inform both sides’ assessments of case value and influence global settlement negotiations. The current status of bellwether trial scheduling in MDL 2973 should be verified through PACER or a qualified attorney.

Who May Have an Elmiron Claim?

Eligibility Criteria

Criterion	Details
Drug use	Prescription record for Elmiron (pentosan polysulfate sodium)
Duration	Typically longer-term use; most claims involve 1+ years of continuous use
Eye diagnosis	Pigmentary maculopathy or other retinal changes confirmed by retinal specialist/ophthalmologist
Functional impairment	Vision loss affecting reading, daily activities
Statute of limitations	Not expired

Strong vs. Weaker Claims

Stronger claim indicators:

5+ years of continuous Elmiron use
Clear maculopathy diagnosis documented by retinal imaging
Functional vision loss (reading disability, dark adaptation impairment)
No alternative diagnosis explaining the macular pattern (no AMD, no diabetic maculopathy)

Weaker claim indicators:

Very short use period (weeks to a few months)
No documented retinal changes on imaging
Macular condition fully explained by another diagnosis

Statute of Limitations by State

State	Products Liability SOL	Discovery Rule
New Jersey	2 years	Yes
California	2 years	Yes
New York	3 years	Yes
Texas	2 years	Limited
Florida	2 years	Yes
Illinois	2 years	Yes
Pennsylvania	2 years	Yes

The June 2020 FDA black box warning is likely the earliest date courts could impute constructive knowledge to patients. For patients diagnosed with maculopathy in 2020, many 2-year SOL deadlines have already passed (2022). For those diagnosed in 2022–2024, deadlines may be 2024–2026. Immediate legal consultation is essential.

Hypothetical Claimant Scenarios

Scenario 1: Long-Term User With Confirmed Maculopathy

Profile: Linda, 54, took Elmiron from 2010 to 2021 for IC. In February 2022, a retinal specialist confirmed pigmentary maculopathy with significant reading difficulty.

Analysis: 11 years of use; confirmed maculopathy diagnosis; functional reading impairment. February 2022 diagnosis + 2-year SOL = deadline February 2024 in most states. If Linda consulted an attorney and filed before that date, her case may have been consolidated into MDL 2973 or is proceeding individually. If not, the discovery rule argument needs immediate attorney evaluation.

Scenario 2: Maculopathy Discovered During Routine Screening

Profile: Angela, 48, has been on Elmiron since 2016. Had no obvious symptoms but during a 2024 annual eye exam, her optometrist noticed abnormal retinal pigment changes and referred her to a retinal specialist, who confirmed maculopathy in March 2024.

Analysis: March 2024 diagnosis; 2-year SOL → March 2026 deadline in most states. Angela is in a favorable time window. She should consult a mass tort attorney immediately to discuss filing in MDL 2973 or state court.

Scenario 3: Stopped Elmiron After 2020 Warning

Profile: Diane, 61, had been taking Elmiron from 2008 to 2020 when her physician stopped the medication after the FDA black box warning. She had a retinal exam in 2021 showing early maculopathy changes. No significant functional vision loss yet.

Analysis: The 2021 maculopathy diagnosis is key. If her state applies a 2-year SOL from 2021, her deadline may have been 2023. The discovery rule (she may have only meaningfully understood the legal connection later) is the best argument for extending the window. Immediate attorney consultation to assess whether the statute has run.

Key Takeaways

MDL 2973 (In re: Elmiron) is before Judge Brian R. Martinotti in the District of New Jersey.
Primary defendant: Janssen Pharmaceuticals (J&J subsidiary); core legal theory is failure to warn.
Research shows ~25% of 5+ year users develop pigmentary maculopathy — a potentially permanent, unique pattern of retinal damage.
FDA added a black box warning in June 2020.
As of October 2025, ~730 cases pending (down from ~2,000, reflecting confidential settlements).
If you are a long-term Elmiron user experiencing vision changes, see a retinal specialist and consult an attorney immediately.

Disclaimer: This post is for general information only and not legal advice. Consult a licensed US attorney for your specific situation.

What court handles MDL 2973 Elmiron litigation?

MDL 2973 — In re: Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation — is centralized in the U.S. District Court for the District of New Jersey, before Judge Brian R. Martinotti. The MDL was established in December 2020. Verify current docket status on PACER.

What is Elmiron and why is it prescribed?

Elmiron (pentosan polysulfate sodium, PPS) is the only FDA-approved oral medication for interstitial cystitis — a chronic bladder pain condition affecting up to 12 million Americans. Manufactured by Janssen Pharmaceuticals (a Johnson & Johnson subsidiary), it has been prescribed since 1996 and is often taken for years or decades.

What eye damage is linked to Elmiron?

Long-term Elmiron use has been linked to pigmentary maculopathy — a distinctive pattern of retinal damage affecting the retinal pigment epithelium (RPE) cells. Research suggests approximately 1 in 4 patients who took Elmiron for 5 or more years developed significant retinal damage.

When did the FDA add a warning about eye damage?

In June 2020, the FDA approved label changes adding a black box warning (the agency's strongest safety alert) for retinal pigmentary changes and maculopathy risk associated with Elmiron use.

What is the current status of MDL 2973?

Approximately 2,000 lawsuits were consolidated into MDL 2973 in December 2020. As of October 2025, roughly 730 cases remain pending. The declining case count suggests confidential settlements are being reached. Verify current docket on PACER.

Can I still file an Elmiron lawsuit in 2026?

Some legal sources as of late 2025 noted that fewer attorneys are actively taking new Elmiron cases. However, if your statute of limitations has not expired, legal options may still exist. Consult a mass tort attorney directly — circumstances change and each case is individual.

What symptoms should prompt me to see a doctor and attorney?

Seek an eye examination from a retinal specialist if you have taken Elmiron for months or years and experience: difficulty reading, trouble adjusting to dim lighting, blurred vision, blind spots, distorted vision (straight lines appearing curved), or color perception changes.

Who are the defendants in Elmiron lawsuits?

The primary defendant is Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson. Plaintiffs allege Janssen knew or should have known about maculopathy risk earlier and failed to adequately warn patients and physicians.

What is the statute of limitations for Elmiron claims?

Most states allow 2–3 years from the date of maculopathy diagnosis or from when you knew or should have known about the Elmiron-maculopathy connection. Given the June 2020 FDA black box warning, courts may find knowledge was imputed in 2020 for many patients.

Is Elmiron maculopathy reversible?

Current research suggests the retinal damage may be permanent in many cases. Some patients report stabilization after stopping Elmiron, but significant functional vision loss — particularly for reading — may not recover. This permanence is central to the damages calculation in lawsuits.

Asbestos Trust Fund Claims for US Navy Veterans With Mesothelioma: 2026 Guide

Elmiron Maculopathy Vision Loss Lawsuit MDL 2973: Eligibility and Claims Guide 2026

What Is Elmiron and Who Uses It?